-Scroll.in One persons died in Mumbai after allegedly being administered with Orofer FCM. The Maharashtra Food and Drug Administration has announced that it will recall a batch of anti-anaemic medicine Orofer FCM after noting multiple incidents of alleged adverse reaction, including the suspected death of a 55-year-old man in Mumbai in September. Orofer FCM is manufactured by Pune-based Emcure Pharmaceuticals, which supplies medicines to 70 countries. It is administered in the form of...

-TheWire.in The US drug regulator says Lupin Limited's response to tackling genotoxic impurities was not adequate. New Delhi: The US Food and Drug Administration (FDA) has sent a warning letter to the Indian pharmaceutical company Lupin Limited after deeming its efforts to address violations of various good manufacturing practices at its facility in Tarapur, Maharashtra “inadequate”. The FDA sends a ‘warning letter’ to a manufacturer if it has “significantly violated” the agency’s regulations....

In the month of April this year, there has been an unprecedented upsurge in daily new cases and daily new deaths in the country due to Covid-19. States, which reported large increases in daily new cases and daily new deaths, are Maharashtra, Kerala, Karnataka, Delhi and Uttar Pradesh, to name but a few.   Data accessed from https://www.covid19india.org/, which is a crowdsourced platform and an independent aggregator of daily Covid-19 figures and...

-The Indian Express With the spotlight on packaged foods’ failure to clear safety tests, The Indian Express samples 11 states and finds out how ill-equipped and understaffed their labs are. For a processed food market estimated at Rs 7.34 lakh crore by the Annual Survey of Industries, 72 state labs and 68 private ones with National Accrediation Board for Testing and Calibration Laboratories (NABL) accreditation are conducting tests in India’s 640...

-Economic and Political Weekly The key to improving the quality of healthcare services in India and reducing costs at the same time can be found by enacting legislation which lays down minimum standards of patient care. In the absence of such standards and the reluctance of health insurance companies to standardise either price or quality, healthcare services continue to be expensive and of doubtful quality. Developing standards of patient care by...